KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to -$117.8 million.

  • Sarepta Therapeutics' Cash from Financing Activities fell 956.22% to -$117.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.1 million, marking a year-over-year decrease of 203.07%. This contributed to the annual value of $124.8 million for FY2024, which is 0.16% down from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Cash from Financing Activities is -$117.8 million, which was down 394.56% from -$23.8 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Cash from Financing Activities high stood at $549.2 million for Q4 2021, and its period low was -$117.8 million during Q3 2025.
  • In the last 3 years, Sarepta Therapeutics' Cash from Financing Activities had a median value of $13.8 million in 2024 and averaged $11.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 3,567.05% in 2022, then crashed by 956.22% in 2025.
  • Sarepta Therapeutics' Cash from Financing Activities (Quarterly) stood at $549.2 million in 2021, then plummeted by 98.04% to $10.7 million in 2022, then slumped by 81.92% to $1.9 million in 2023, then skyrocketed by 2,421.41% to $49.0 million in 2024, then tumbled by 956.22% to -$117.8 million in 2025.
  • Its last three reported values are -$117.8 million in Q3 2025, -$23.8 million for Q2 2025, and $12.5 million during Q1 2025.